Bemdaneprocel in the treatment of Parkinson’s disease

The standard of care for Parkinson’s disease has seen nominal improvement in the last 60 years.

We’re working to change that

A drawing of a neuron

About Parkinson's Disease

Learn More about Neurology

Dopaminergic neurons are lost in Parkinson’s disease-mediated neurodegeneration. We can differentiate PSCs into dopaminergic neurons that have the potential to reform the neural networks that were destroyed, and restore motor function. Bemdaneprocel, our lead clinical stage program, is a stem cell-derived therapy that surgically transplants dopamine-producing neurons into the brain.

The safety and preliminary efficacy of bemdaneprocel (BRT-DA01) is being evaluated in a Phase 1 clinical trial with twelve patients in the United States and Canada.

BlueRock expects to share preliminary results from the clinical trial in the second half of 2023.

A BlueRock Therapeutics scientists smiling in a lab

We're working for patients

Keeping the lights on.

We're working for families and caregivers

Who are also on this journey.